Insulin aspart (AT278) vs insulin NPH
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
Insulin aspart (AT278)
Developed by Arecor Limited
NCT05754424 · Phase 1 · completed
Every participant received AT278 and the active comparator insulin in random order, with neither participants nor staff knowing which was given at each visit, which is a solid design. But the trial measured a pharmacology lab readout rather than a real-world blood sugar or complication outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Area under the glucose infusion rate-time curve of insulin aspart (0 to 60 minutes): Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). (met)
Result source: NCT05754424
insulin NPH · Humulin N
Marketed by Eli Lilly
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin aspart (AT278) | insulin NPH |
|---|---|---|
| HbA1c, change | —Not reported | —Not posted · NCT00604396 |
| Body weight, change (kg) | —Not reported | 12.6 vs 13vs LevemirNCT01837680 |
| HbA1c below 7% | —Not reported | —Not posted · NCT00604396 |
| Fasting plasma glucose, change | —Not reported | —Not posted · NCT00604396 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT00604396 |
HbA1c, change
- Insulin aspart (AT278)
- —Not reported
- insulin NPH
- —Not posted · NCT00604396
Body weight, change (kg)
- Insulin aspart (AT278)
- —Not reported
- insulin NPH
- 12.6 vs 13vs LevemirNCT01837680
HbA1c below 7%
- Insulin aspart (AT278)
- —Not reported
- insulin NPH
- —Not posted · NCT00604396
Fasting plasma glucose, change
- Insulin aspart (AT278)
- —Not reported
- insulin NPH
- —Not posted · NCT00604396
3-point MACE (% with event)
- Insulin aspart (AT278)
- —Not reported
- insulin NPH
- —Not posted · NCT00604396
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin aspart (AT278): 0 of 4 rows · insulin NPH: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin NPH |
|---|---|
| Dropout rate | 19.2%a NCT01837680 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01837680 · Phase na · registry result, not featured evidence |
| Serious AEs | 0%a NCT01837680 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a biochemical event of hypoglycemia 26.9% symptomatic hypoglycemia 21.2% rash 11.5% NCT01837680 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin NPH
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (AT278)'s landscape · insulin NPH's landscape